Evox Therapeutics Expands Its Exosome Manufacturing Patent Portfolio; Four Newly Issued Patents Cover Key Purification Processes and Methods of Exogenous Loading

On September 7, 2022, Evox Therapeutics Ltd, a leading exosome therapeutics company, today announced that the company has been granted four new patents covering a broad range of exosome manufacturing methods and processes. Evox has been granted US Patent US11,298,319, European patents EP3700566 and EP3569254, and Japanese Patent JP6999601. Taken together these four patents, in three key jurisdictions, provide broad protection for a large range of downstream purification as well as methods of exogenous drug cargo loading which are routinely used by all companies operating in the exosome field. Specifically, the claims cover a method of purifying engineered exosomes via a downstream process utilizing ultrafiltration and size-based separation steps, an affinity chromatography process, and two methods of loading exosomes with a wide range of pharmacological agents including oligonucleotides and small molecules.

Login Or Register To Read Full Story